Breast cancer patients denied life-extending drug in cost row
The drug, called Enhertu, can give patients with a specific type of incurable breast cancer an extra six months to live on average. The health assessment body, NICE, is the only organisation around the world so far to say no to the drug for this condition. It says that it is too expensive for the NHS to fund.